Corpus Intelligence IC Memo — CRESCENT MEDICAL CENTER LANCASTER 2026-04-26 14:30 UTC
IC Memo — CRESCENT MEDICAL CENTER LANCASTER
Investment Committee Memorandum | TX | 84 beds | Grade D | EBITDA uplift $3.1M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CRESCENT MEDICAL CENTER LANCASTER

CCN 670090 | DALLAS, TX | 84 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

CRESCENT MEDICAL CENTER LANCASTER is a 84-bed under-performing / distressed in DALLAS, TX with $41.8M in net patient revenue and a -6.2% operating margin. The hospital serves a payer mix of 16.3% Medicare, 1.1% Medicaid, and 82.6% commercial.

Thesis: Turnaround. Our ML models identify $3.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -6.2% to 1.1% (+736bps).

Net Revenue HCRIS$41.8M
Current EBITDA COMPUTED$-2.6M
Operating Margin COMPUTED-6.2%
Occupancy HCRIS11.1%
Revenue / Bed COMPUTED$498K
Net-to-Gross HCRIS16.9%
Distress Probability ML55.4%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
204
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -6.2% places it below the state median. Among 204 size-comparable peers (42-168 beds), the median margin is 2.0%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (42-168), prioritizing same-state peers. 204 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CRESCENT MEDICAL CENTER LANCAS (Target)TX84$41.8M-6.2%
ROUND ROCK HOSPITALTX165$681.4M8.7%
THE HEART HOSPITAL BAYLOR PLANTX109$464.6M25.7%
COLLEGE STATION HOSPITALTX135$397.7M-0.9%
DECATUR COMMUNITY HOSPITALTX81$361.0M-15.5%
CHILDRENS MEDICAL CENTER OF PLTX72$336.7M20.9%
MEDICAL CITY MCKINNEYTX166$302.5M-0.4%
ROUND ROCK MEDICAL CENTERTX161$296.7M25.7%
BAYLOR SW MEDICAL CENTER- WAXATX123$273.6M15.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.1M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$878K+210bp18mo
Cost to Collect4.5%2.5%$836K+200bp12mo
Denial Rate Reduction12.0%6.5%$828K+198bp12mo
A/R Days Reduction5200.0%3800.0%$509K+122bp9mo
Clean Claim Rate88.0%96.0%$27K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$878K
Cost to Collect
$836K
Denial Rate Reduction
$828K
A/R Days Reduction
$509K
Clean Claim Rate
$27K
Total EBITDA Uplift$3.1M
Current EBITDA$-2.6M
+ RCM Uplift+$3.1M
Pro Forma EBITDA$478K
Current Margin-6.2%
Pro Forma Margin1.1%
WC Released (1x)$1.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-4.0M$13.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-4.0M$13.7M0.00x-100.0%
Bull Case9.0x11.0x$-3.6M$22.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-3.6M$23.5M0.00x-100.0%
Bear Case11.0x10.0x$-4.4M$-460K0.00x-100.0%
Bear (11x exit)11.0x11.0x$-4.4M$-1.9M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 11.1%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 55.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 204 hospitals with 42-168 beds
  • Same-state prioritization (n=205)
  • Comp margins: P25=-11.5% / P50=2.0% / P75=11.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.